HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader

CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI.